Colorectal Cancer Clinical Trials in Tennessee

Showing 61-80 of 359 trials

Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors

NCT05731947

This study will evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of revumenib in participants with colorectal cancer (CRC) or other solid tumors who have failed at least 1 prior line of therapy.

Colorectal CancerSolid Tumors

Syndax Pharmaceuticals42 participantsStarted Apr 2023

Scottsdale, Arizona, United States • Boston, Massachusetts, United States • Manhattan, New York, United States +3 more locations

TERMINATEDPhase 129 miles

A Study of PHN-010 in Patients With Advanced Solid Tumors

NCT06457997

This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-010, a novel antibody-drug conjugate (ADC), in patients with advanced solid tumors.

Lung CancerColon CancerEndometrial Cancer+4 more

Pheon Therapeutics26 participantsStarted Jul 2024

Orlando, Florida, United States • Boston, Massachusetts, United States • New York, New York, United States +5 more locations

Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors

A Study of PHN-010 in Patients With Advanced Solid Tumors

Colorectal Cancer Trials in Other Cities

Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer

Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer

A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

EXoPERT EMERALD Clinical Study

Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation

Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer

A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers

Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors

Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors

Radiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer

A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors

Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours

Community Collaboration to Advance Racial/Ethnic Equity in CRC Screening

Early Onset Colorectal Cancer Detection

Other Conditions in Tennessee